12.2.2016

Rims Hit Regulation: Replica Rims and the Spare Part Exception

We all know that design is one of the key features that car manufacturers focus on to build their brands and develop a loyal customer base. This is particularly true of premium car brands.

Of course, the value of high-end design makes a tempting target for manufacturers and sellers for after-sales parts. This has brought them into conflict with car manufacturers who, naturally, want to protect their intellectual property.

This was the issue at the heart of a recent dispute between BMW and an importer and seller of replica rims.

Copies Cause a Tug of War

BMW has protected the design of its rims on the EU-level by registering them as Community Designs. When BMW became aware of the replica rims, BMW took action against them.

The importer of the replica rims argued that the rims were legal, because they were covered by Article 110(1) of the Community Designs Regulation known as the spare parts exception. This exception essentially states that the owner of a Community Design cannot prevent other parties from manufacturing and selling spare parts.

Given that the regulation is a political compromise that leaves the definition of what exactly is considered a spare part somewhat unclear, the ground was set for the dispute.

Replica Rims Are Not Spare Parts

The scope of the spare part exception has been contested throughout Europe over the past years in various proceedings, typically between car manufacturers and spare part producers or their retailers.

In this Finnish case, the key arguments revolved around a part of the wording of the exception that states that for the exception to apply, the part must be used ‘for the purpose of the repair of [a] complex product so as to restore its original appearance’. In this case, the complex product was a car.

The Helsinki District Court found that rims are not used to ‘restore the original appearance’ of a car, but to improve or modify it. This being the case, the replica rims were not considered spare parts and not protected by the exception.

Rims Alter, Nor Restore, a Car’s Appearance

In its reasoning, the Court compared rims to a front wing of a car. In the Court’s view, a spare part front wing must be identical with the one being replaced, but aluminium rims are used to give the car a different, typically more trendy, appearance.

From a legal perspective, the District Court followed the dominant approach in European case law, citing the recent ruling of the Danish Supreme Court from 10 March 2015 and the well-known decision of the UK High Court in BMW v Round and Metal from 2012 in support of its reasoning

More Certainty for Design Rights Holders

Even though the decision is in line with European case law, it remains precedent setting in Finland. Owners of Community Designs now have more certainty when seeking to intervene in the sale of replica rims in Finland.

If you’re interested in Community design rights, the spare part exception and perhaps EU trade mark law, you should have a look at the recent decision of the Court of Justice of the European Union (CJEU) in Ford Motor Company vs Wheeltrims Srl (C-500/14). In that case the CJEU, responding to a preliminary reference, held, some might say unsurprisingly, that the spare part exception under Article 110(1) does not provide a defence to an alleged trademark infringement.

Full disclaimer: we acted for BMW in the dispute.

Sakari Salonen

Kim Parviainen

Latest references

We are acting as the lead counsel to Fortum in a cross-border transaction in which Fortum is selling its recycling and waste business. The business is sold to thematic impact investing firm Summa Equity through its portfolio company NG Group. The debt-free purchase price is approximately EUR 800 million. The transaction is subject to authority approval and customary closing conditions. Fortum’s recycling and waste business to be sold comprises municipal and industrial waste management and end-to-end plastics, metals, ash, slag and hazardous waste treatment and recycling services. These businesses are located in Finland, Sweden, Denmark and Norway and currently employ approximately 900 employees.
Case published 18.7.2024
We successfully represented Onses Finland Oy before the Finnish Market Court in an exceptionally extensive dispute concerning alleged trademark infringement and unfair business practice. Our client, Onses Finland Oy, is a Finnish sports drink company and the owner of the sports drink brand ONSE. In the spring of 2023, the Polish beverage company OSHEE Polska Sp. z o.o. filed legal action against our client, alleging that the ONSE trademarks and product packaging infringed the OSHEE trademarks. The plaintiff’s secondary claims concerned alleged slavish imitation of the OSHEE sports drink packaging and exploitation of the reputation of the plaintiff. The plaintiff based its suit on registered trademarks as well as allegedly established and reputed figurative and three-dimensional trademarks. The Market Court rejected all of the plaintiff’s claims. The Market Court held that the marks invoked in the suit were neither established nor marks with a reputation in Finland. As regards the registered trademarks, the Market Court found that there was no likelihood of confusion between the OSHEE and ONSE trademarks. As to the secondary claims, the Market Court held that the sports drink packaging used by the plaintiff was a normal beverage bottle, the design of which was partly determined by functional factors. The Market Court also found that there were several blue sports drinks available on the market and that the plaintiff’s product was not the first blue sports drink on the market. The plaintiff failed to show that its product packaging was original or well-known to the average consumer at the time of the launch of our client’s ONSE sports drink product, and the Market Court thus rejected the claims on slavish imitation and exploitation of reputation. The Market Court ordered the plaintiff to pay all of our client’s legal costs with statutory interest. The judgment (MAO:280/2024) is not final.
Case published 11.6.2024
We acted as the legal and ESG advisor to Mérieux Equity Partners on the acquisition of a majority stake in Labquality through a leveraged buyout by its buyout fund, Mérieux Participations 4. Existing shareholders of Labquality, including Cor Group and the management, will reinvest a portion of their proceeds into the company in connection with the transaction. Headquartered in Helsinki, Finland, Labquality is a Nordic player specialized in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. The company, employing over 120 professionals and supported by a network of more than 150 external experts and consultants across its offices in Finland, Germany, and Poland, serves a diverse clientele of over 8,000 customers, including major pharmaceutical companies in over 60 countries. Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. The transaction will enable Labquality to pursue its buy & build strategy in Europe to accelerate its CRO activities while continuing strong and recurring growth in the EQA segment. Labquality will benefit from MxEP’s sector expertise and financial resources to achieve its ambition of becoming a leading European CRO and EQA platform, with fully integrated regulatory consulting capabilities to serve major customers across Europe.
Case published 4.12.2023
We advised Voisin Consulting Life Sciences (VCLS) on the acquisition of MedEngine, a leading medical science agency in the Nordics. MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Founded in 1997, VCLS provides end-to-end HealthTech solutions to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India, and China, VCLS serves a broad range of developers and investors in HealthTech.
Case published 7.11.2023